GILEAD SCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
GILEAD SCIENCES, INC. (GILD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $24.68 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2014-02-25
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2013 was $24.68M, a 118.53% increase from fiscal 2012.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2012 was $11.29M, a 24.01% decline from fiscal 2011.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2011 was $14.86M, a 12.68% increase from fiscal 2010.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2010 was $13.19M, a 208.92% increase from fiscal 2009.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2013-12-31 | $24.68M 10-K · filed 2014-02-25 |
| 2012-12-31 | $11.29M 10-K · filed 2014-02-25 |
| 2011-12-31 | $14.86M 10-K · filed 2014-02-25 |
| 2010-12-31 | $13.19M 10-K · filed 2013-02-27 |
| 2009-12-31 | $4.27M 10-K · filed 2012-02-23 |
| 2008-12-31 | $5.22M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |